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Discharge Abstract Database and National Ambulatory Care Reporting System 
database. All acute care hospitalization discharge abstracts with either conges-
tive heart failure (ICD-10 code I50.0) recorded as the most responsible diagnosis 
(MRDx) or contributing diagnosis amongst patients aged ≥ 18 were included in the 
study. Abstracts with a CHF MRDx were categorized in the CHF group. The remain-
ing abstracts were categorized into either the cardiovascular group (circulatory 
system disease MRDx (ICD-10 I00 – I99), excluding CHF) or non-cardiovascular 
group (non-circulatory system disease MRDx). Discharge abstracts with missing 
demographics, or absent without leave or against medical advice discharge sta-
tus were excluded. Results: 156,847; 66,056; and 127,847 CHF, cardiovascular, 
and non-cardiovascular group discharge abstracts were included, respectively, 
of which 10%, 13% and 21% of the respective group abstracts resulted in death. 
The national mean hospitalization visit cost was $10,123; $20,890; and $21,283 
for the CHF, cardiovascular, and non-cardiovascular groups respectively. For each 
CHF, cardiovascular, and non-cardiovascular group, a survival outcome incurred 
a lower national mean hospitalization visit cost at $9,222; $19,899; and $19,036 
whereas a death outcome incurred a high national mean hospitalization visit cost 
at $18,087; $27,642; and $29,887, respectively. ConClusions: Cardiovascular and 
non-cardiovascular hospitalizations result in higher mean hospitalization costs 
than those with a CHF MRDx. An opportunity exists for interventions reducing 
the number of any CHF related hospitalization to ease the burden on healthcare.
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objeCtives: Randomized clinical trials comparing percutaneous coronary inter-
ventions (PCI) and non-invasive treatment of acute coronary syndromes mostly 
favour the invasive approach. This study aimed at assessing whether in a real 
life setting PCI has an impact on outcomes as hospitalization cost, length of 
stay (LOS) and mortality in patients hospitalized for acute coronary syndromes 
(ACS) in Belgium. Methods: The hospitalization cost, average length of stay 
(LOS) and mortality among hospitalized patients with ACS were estimated using 
the longitudinal IMS Hospital Disease Database (year 2013), including data on 
about 24% of Belgian hospital beds. Stays were identified based on ICD-9 cod-
ing and split in ST-elevated Myocardial infarction (STEMI ICD-9: 410 excluding 
410.7), non-STEMI (NSTEMI: ICD-9: 410.7-411.89) and unstable angina (UA; ICD-9: 
411.1-411.8-413.0). PCIs were identified with ICD-9 code 36.0. Comparisons were 
performed using a Wilcoxon non-parametrical test for cost/ LOS and a Chi-square 
for mortality. Results: 2,528 STEMI, 2,815 NSTEMI and 407 UA hospitalizations 
were retrieved from the database, with respectively 1,457, 1,194 and 30 of them 
treated invasively. PCI resulted in higher costs in STEMI (€ 9,342 vs. € 8,165; p< 0.001) 
and UA (€ 9,186 vs. € 4,714; p< 0.001) and in lower costs in NSTEMI (€ 8,483 vs. € 9,483; 
p< 0.001). LOS of patients undergoing PCI was significantly lower in STEMI (6.2 
vs. 9.7 days; p< 0.001) and NSTEMI (5.6 vs. 10.9; p< 0.001). In-hospital mortality in 
patients with PCI was lower in both STEMI (6.2% vs. 21.4%; p< 0.001) and NSTEMI 
(1.6% vs. 8.0%; p< 0.001). LOS (5.5 vs. 5.9 days) and mortality (0.0% vs. 3.2%) were 
not significantly different in UA. ConClusions: Although information on the 
baseline characteristics of the different patients is limited, the findings of this 
retrospective study seem to support randomized clinical trials. Treatment with PCI 
significantly decreases the LOS and the mortality in patients with a myocardial 
infarction, at a limited marginal cost.
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objeCtives: To evaluate the costs and benefits of Yindanxintai dropping pills 
(Guizhou Junzhitang Pharmaceutical Company) for angina pectoris caused 
by coronary heart disease from the societal perspective. Methods: The com-
parator was chosen from published literature. Treatment results and costs were 
derived from published literature and government websites. A contingent valu-
ation survey was used to elicit the respondents’ willingness-to-pay (WTP) for 
angina pectoris treatments. The WTP was modeled as a function of the treat-
ment outcomes, design of questionnaire scenarios, individual health states and 
characteristics. A total of 351 questionnaires were completed. The primary out-
come was the annual net cost-benefit or incremental net cost-benefit per person 
tested. Results: WTP increased with the growth of effective rate. The average 
WTP was given 377 RMB per month (range 100 RMB to 2000 RMB) to the treatment 
with a 95% effective rate. There were 7 papers that provided adequate information 
to the further cost-benefit analysis (CBA). Results from the CBA indicated that 
Yindanxintai dropping pills had a positive annual net benefit when used alone, 
and the treatment with 56 days was superior to 28 days with an annual incre-
mental net benefit (AINB) of 4529 RMB per person tested. Yindanxintai dropping 
pills used with nitroglycerin tablets (Shanghai Sina Pharmaceutical Company) 
had greater net benefit than simvastatin tablets (Yangtze River Pharmaceutical 
Group) with nitroglycerin tablets (AINB= 1471 RMB). Yindanxintai dropping pills 
used with isosorbide mononitrate sustained release tablets (AstraZeneca AB), 
Xinkang tablets (Lunan Pharmaceutical Company), or Xinkang tablets and Xinke 
tablets (Guangzhou Nanxin Pharmaceutical Company) also had greater net ben-
efit than the other drugs used alone (AINB were 306 RMB, 479 RMB, 1067 RMB, 
respectively). The results of this research were proved robust through sensitivity 
analyses. ConClusions: Yindanxintai dropping pills is cost-beneficial in the 
treatment of angina pectoris caused by coronary heart disease either used alone 
or used with other drugs.
clinical course of DVT may also be complicated by recurrent episodes of DVT, the 
development of post-thrombotic syndrome (PTS), as well as chronic thromboem-
bolic pulmonary hypertension (CTEPH). The aim of study was to estimate the cost 
of VTE treatment in Turkey. Methods: The study was undertaken from the Turkish 
health care payer perspective. (SSI). An Excel sheet was formed to determine the 
healthcare resources used in treatment of VTE. VTE treatment costs were divided 
by anticoagulant use, monitoring INR, recurrent DVT, recurrent PE, non IC major 
bleeding (GIS), Intracranial bleed, CTEPH and PTS long term costs.Resource utiliza-
tion data were obtained via expert clinical views and included diagnosis costs and 
treatment costs. Unit costs were taken from the Social Security Institution’s Health 
Implementation Guideline. Results: According to the results of the study,cost 
ofanticoagulans were146,59 TL, monitoring INR costs were 90,00 TL, recurrent DVT 
costs were 1.972,41 TL, recurrent PE costs were 830,49 TL, non IC major bleeding 
(GIS) costs were 1.482,49, Intracranial bleed costs were 3.868,86 TL, CTEPH costs were 
22.228,12 TL and PTS long term costs were 754,29 TL in Turkey. ConClusions: The 
study showed that VTE treatment poses a high treatment cost due to recurrence 
and OAC complications in the Turkish health care system.
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objeCtives: Vietnam spends 6% of its GDP to health care. In context of insuf-
ficient evidence on quantifying the economic burden of cardiovascular disease in 
Vietnam, we conducted a study on the costs of Acute Myocardial Infarction (AMI). 
Costs were identified from the perspective of the health care payers, including 
health insurance providers and patients. Methods: Data was extracted from the 
database of a regional hospital in Vietnam. All patients with the single code I21 
according to the International Clarification of Disease 10 were included in the study. 
Costs were calculated in year 2013. Out-of-pockets payment was quantified as the 
net of health insurance (HI) reimbursement and actual payments. Results: 89 
patient-hospitalizations were included in the study, including 34 cases requiring 
percutaneous coronary intervention and 55 cases requiring medicine only. Mean 
costs of AMI were US$ 2,503 (+/-3,377) per hospitalization. Costs per hospitalization 
were higher in the group requiring percutaneous coronary intervention than in the 
group requiring medicine only at US$5,962 (+/- 3,197) and US$365 (+/- 401), respec-
tively. Out-of-pocket payments were approximately 60% of these costs. Generally, 
cost of AMI per hospitalization in Vietnam was higher than GDP per capita (US$ 
1,900). ConClusions: Our results indicate that MI prevention is needed to reduce 
the burden of disease as well as to avoid catastrophic expenditure and impoverish-
ment problemsin Vietnam. Our results also comprise essential building blocks for 
important variables in a future cost-effectiveness modeling exercise on cardiovas-
cular prevention.
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objeCtives: to compare the total treatment duration cost per patient between the 
two most used low-molecular-weight heparins (LMWHs) in Spain for the prophy-
laxis of the venous thromboembolism disease (VTE) and the treatment of deep 
vein thrombosis (DVT) with and without pulmonary embolism (EP), during the 
acute phase and at long term. Methods: patients in prophylaxis were classified 
as moderate or high according to the risk of the surgery. Patients with high risk 
were further classified by surgery type: 1) orthopedic or oncologic surgery, 2) other 
surgeries, and 3) medical patients (surgery is not performed by a surgical speciality 
but other specialists). Patients with DVT were divided into 10 kilogramme weight 
ranges as well as considering the distribution of the Spanish population in each 
range taken from the RIETE registry. Treatment duration was obtained from clini-
cal guidelines. Treatment duration and patient profile defined the strength and 
package size used to estimate the cost per patient in prophylaxis. Concerning 
DVT, only the most appropriate strengths for each weight range were considered. 
Costs are expressed in € of 2015 and calculated based on the retail price plus the 
value-added tax of each LMWH discounting the corresponding deduction accord-
ing to Royal Decrees. Results: administering enoxaparine instead of bemiparine 
represents a saving of 6€ (5%), 7€ (16%) and 7€ (16%) per patient per total treatment 
duration with high risk undergoing surgery type 1, 2 and 3, respectively, and 4€ 
(16%) per patient per total treatment duration with moderate risk. Average sav-
ings per patient per total treatment duration with DVT came to 61€ (56%) and 
354€ (46%) in the acute phase and at long term, respectively. ConClusions: the 
cost of treating VTE or DVT is lower when administering enoxaparine instead of 
bemiparine. Therefore, the use of enoxaparine represents an economic benefit 
for the Spanish health system.
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objeCtives: Chronic heart failure (CHF) affects more than 600,000 Canadians, 
resulting in thousands of hospitalizations and deaths each year. This study’s objec-
tive is to compare the mean cost ($CAD) of a CHF, cardiovascular, and non-cardi-
ovascular diagnosed hospitalization amongst acute care treated CHF diagnosed 
patients. This study builds upon previously presented Canadian CHF hospitaliza-
tion costing research. Methods: Hospital discharge abstracts recorded between 
2009 and 2013 were extracted from the Canadian Institute for Health Information’s 
